Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Subcutaneous Amlitelimab for Hidradenitis Suppurativa
Recruiting0 awardsPhase 2
Margate, Florida
This trial will assess the efficacy, safety, and drug concentration of a subcutaneous injection of amlitelimab compared to placebo in people aged 18-70 with moderate to severe hidradenitis suppurativa. It will last up to 116 weeks, with up to 6 in-clinic visits in the double-blind period and 8-12 in the open-label extension.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.